|
RESprotect
Name
Address/P.O. Box
Postal Code/City
State
Contact Person
Telephone
Fax
Email Address
Internet Website
Number of Employees
Founded (year)
Type of Laboratory
Areas of Activity
Annual Turnover
Relevant R&D Budget
Biological Patents
External Collaborations
Request for
Further Collaborations
|
RESprotect GmbH
Fiedlerstr. 34
D-01307 Dresden
Saxony
Prof. Dr. Rudolf Fahrig
+49-351-4503200
+49-351-4503210
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
www.resprotect.com
10
2000
S1
Cancer chemotherapy;
Chemotherapy of infectious diseases
n.a.
n.a.
n.a.
WITEGA/Berlin; Nycomed/Linz,
Austria; ERCOM/Budapest,
Hungary; Clinics Chemnitz;
University Leipzig; University
Munich; Technical University
Munich;University Vienna/
Austria; Avantogen/San Diego,
USA.
Partnering: RESprotect is looking for the appropriate partner to develop its key project RP101 in Europe, South America and Asia,
and its follow-on compounds worlwide.
|
- RESprotect - Prevention of Chemoresistance - Overview
RESprotect GmbH is a privately owned biotechnology company located in Dresden Germany. RESprotect is focusing on the inhibition of chemoresistance and the enhancement of chemosensitivity. In contrast to the well known efforts to circumvent or decrease existing chemoresistance, this basic approach is unrivalled. RESprotect was founded in 2000. The founder is geneticist and came from the Fraunhofer-Institute for Toxicology in Hannover. At present clinical studies with RP101 in the pancreas cancer indication, exploratory research in the identification of next generation of New Chemical Entities (NCEs) and general broadening of clinical indications are underway. RESprotect is in a position to enter exclusively a segment in the huge market of anticancer cytostatics. Use patents exist and extension of the patent portfolio by substance patents is achieved. New chemical entities have been identified and introduced to the development pipeline.
- Combating Chemoresistance - Chemogenomics Enters the Battleground
In cancer model systems, chemoresistance is often mediated by a single gene, and, therefore, may in theory be inhibited by any drug that targets the product of that gene. All these drugs possess potency and specificity exclusively for only one of the several reasons for chemoresistance. In this respect, the chemogenomics approach focuses on small molecules, causing favorable phenotypic changes, and inhibiting or preventing the induction of chemoresistance. The drugs have to counteract the over-expression of apoptosis-antagonizing genes and to enhance the immune responses. By influencing not only one but a number of different validated targets a new class of effective anti-cancer drugs will be developed. These compounds have to be administered in addition to standard chemotherapy. RP101 is the first drug that shows these effects in tumor cells in culture, in animals and in patients. RP101 improves the efficacy of chemotherapy in treating pancreatic carcinoma cells or patients.
In pre-clinical studies, RP101 has shown strong antitumor effects due to inhibition of
|
